T1	Participants 253 292	patients with overactive bladder (OAB).
T2	Participants 392 547	patients with continuous OAB symptoms for ≥ 3 months, daily mean voiding frequency (DMVF) ≥ 8, and daily mean urgency or urgency incontinence frequency ≥ 2
